ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and is associated with poor prognostic features such as triple negative and poorly differentiated tumors and may be biomarker candidates for breast cancer survival prediction in high risk populations such as HER2+ cases (Sobral-Leite et al., 2015). The gene discussed is ERBB2; the disease is breast carcinoma.